A recent study by Olivieri , published in , reports that between 2009 and 2015 a third of patients with thalassaemia in Canada's largest hospital were switched from first-line licensed drugs to regimens of deferiprone, an unlicensed drug of unproven safety and efficacy. Based on retrospective data from patient records, the PLOS Study reports that patients treated with deferiprone, either as monotherapy or in combination with first-line drugs, suffered serious (and often irreversible) adverse effects. The data reported by Olivieri give rise to a number of ethical issues. These ethical issues are identified, placed in historical context and analysed. For purposes of this analysis, reliance is placed on two core principles of research ethics, harm minimisation and informed consent, and also on the hospital's mission statement. Then a mystery is explored: How and why did it happen that Toronto's University Health Network treated large numbers of patients with an unlicensed drug over a period of many years? 'Institutional conflict of interest' is considered as a possible explanatory hypothesis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/medethics-2019-105498 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Access to child-appropriate medicines: an exploratory survey of the use of paediatric use marketing authorisation products in the UK.
Eur J Pediatr
January 2025
Pharmacy Department, Guy's and St Thomas' NHS Foundation Trust, Evelina London Children's Hospital, Westminster Bridge Road, London, SE1 7EH, UK.
The Paediatric Use Marketing Authorisation (PUMA) was introduced in the European Union to incentivise the development of off-patent medicines in children. However, there is limited data on the accessibility of PUMA products at the healthcare provider level. This study aimed to identify factors affecting real-world accessibility to PUMA products in the United Kingdom (UK).
View Article and Find Full Text PDFPatient-driven personal importation in the face of cost barriers to care: can we do better?
Intern Med J
January 2025
Faculty of Medicine, UNSW Sydney, St Vincent's Clinical School, Sydney, New South Wales, Australia.
Australia has a robust public health system that helps to make medicines affordable. However, evidence shows that a significant proportion of Australians still cannot afford medicines prescribed to them and that some patients import medicines from abroad as a result. The strongest predictor of whether patients import medicines is whether they have discussed it with their doctor.
View Article and Find Full Text PDFIn August 2024, The U.S. Food and Drug Administration rejected Lykos Therapeutics, Inc.
View Article and Find Full Text PDFEvaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.
Clin Pharmacokinet
January 2025
Clinical Pharmacology, AbbVie Inc., Dept R4PK, Bldg AP31-3, 1 North Waukegan Road, North Chicago, IL, 60064-1802, USA.
Background And Objective: The objective of this study was to characterize the effects of risankizumab on the pharmacokinetics of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A substrates in patients with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC) using a cocktail approach.
Methods: Patients with CD or UC (n = 20) received single doses of probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) before and after intravenous infusions of risankizumab 1800 mg once every 4 weeks for four doses. Serial blood samples were collected for determination of concentrations of the CYP probe drugs and metabolites with and without risankizumab.
Antipsychotic medications and risk of respiratory failure in the respiratory high dependency unit.
BJPsych Open
December 2024
Faculty of Medicine, University of Queensland, Brisbane, Australia.
Background: There is a high incidence of serious mental illness (SMI) and antipsychotic use in the respiratory high dependence unit (HDU) compared with the general population. However, there is a paucity of data in the extant literature evaluating the relationships between respiratory failure and antipsychotics.
Aims: To investigate the relationship between antipsychotics and respiratory failure in people admitted to a respiratory HDU, and to gain a better understanding of the potential impact of antipsychotic medications on respiratory outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!